Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 11 points (-0.1%) at 15,227 as of Tuesday, June 11, 2013, 12:50 PM ET. The NYSE advances/declines ratio sits at 560 issues advancing vs. 2,425 declining with 97 unchanged. The Drugs industry currently sits up 0.1% versus the S&P 500, which is down 0.37. Top gainers within the industry include Alexion Pharmaceuticals ( ALXN), up 3.8%, Celgene Corporation ( CELG), up 1.5% and Amgen ( AMGN), up 0.5%. On the negative front, top decliners within the industry include Merck ( MRK), down 1.10, and Novartis ( NVS), down 0.47. TheStreet Ratings group would like to highlight 4 stocks pushing the industry higher today: 4. Novo Nordisk A/S ( NVO) is one of the companies pushing the Drugs industry higher today. As of noon trading, Novo Nordisk A/S is up $2.27 (1.39) to $166.02 on average volume Thus far, 157,887 shares of Novo Nordisk A/S exchanged hands as compared to its average daily volume of 276,400 shares. The stock has ranged in price between $165.51-$166.78 after having opened the day at $165.84 as compared to the previous trading day's close of $163.75. Novo Nordisk A/S engages in the discovery, development, manufacture, and marketing of pharmaceutical products primarily in Denmark. It operates in two segments, Diabetes Care and Biopharmaceuticals. Novo Nordisk A/S has a market cap of $89.6 billion and is part of the health care sector. The company has a P/E ratio of 4.0, below the S&P 500 P/E ratio of 17.7. Shares are down 0.2% year to date as of the close of trading on Monday. Currently there are 2 analysts that rate Novo Nordisk A/S a buy, 1 analyst rates it a sell, and 1 rates it a hold. TheStreet Ratings rates Novo Nordisk A/S as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, impressive record of earnings per share growth, compelling growth in net income, notable return on equity and expanding profit margins. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Novo Nordisk A/S Ratings Report now. 3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.